Peking University Peoples Hospital

Kintor Pharma's KX-826 tincture 1.0% achieved its primary endpoint in a Phase II clinical trial for male androgenetic alopecia treatment.

Alebund Pharmaceuticals announced that its investigational drug AP301, a novel fiber-iron-based phosphate binder, met its primary endpoint in a pivotal phase 3 study for controlling serum phosphorus in dialysis patients with hyperphosphatemia.

• HTD1801, a plant-derived berberine medication, demonstrated significant blood glucose control in type 2 diabetes patients, with the highest dose reducing HbA1c by 0.7% over 12 weeks. • The phase 2 trial involving 113 patients showed HTD1801 improved multiple health markers, including glucose metabolism, insulin resistance, and cardiovascular parameters. • The drug was generally well-tolerated, with mostly mild to moderate side effects, positioning it as a potential new oral treatment option for type 2 diabetes management.

Wegovy, a weight-loss drug containing semaglutide, has been introduced in China, offering a new treatment option for the country's increasing obese population.

Innovent Biologics announced that mazdutide, a novel GLP-1R/GCGR dual agonist, successfully met all primary and key secondary endpoints in the GLORY-1 Phase 3 trial for weight management in Chinese adults with overweight or obesity.